BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 38129784)

  • 1. MYO5A overexpression promotes invasion and correlates with low lymphocyte infiltration in head and neck squamous carcinoma.
    Xing J; Gu Y; Song Y; Liu Q; Chen Q; Han P; Shen Z; Li H; Zhang S; Bai Y; Ma J; Sui F
    BMC Cancer; 2023 Dec; 23(1):1267. PubMed ID: 38129784
    [TBL] [Abstract][Full Text] [Related]  

  • 2. FDCSP Is an Immune-Associated Prognostic Biomarker in HPV-Positive Head and Neck Squamous Carcinoma.
    Wu Q; Shao T; Huang G; Zheng Z; Jiang Y; Zeng W; Lv X
    Biomolecules; 2022 Oct; 12(10):. PubMed ID: 36291667
    [No Abstract]   [Full Text] [Related]  

  • 3. Sterol regulatory element binding transcription factor 1 promotes proliferation and migration in head and neck squamous cell carcinoma.
    Tan M; Lin X; Chen H; Ye W; Yi J; Li C; Liu J; Su J
    PeerJ; 2023; 11():e15203. PubMed ID: 37090107
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CCR5 as a prognostic biomarker correlated with immune infiltrates in head and neck squamous cell carcinoma by bioinformatic study.
    Li C; Chen S; Liu C; Mo C; Gong W; Hu J; He M; Xie L; Hou X; Tang J; Ou M
    Hereditas; 2022 Sep; 159(1):37. PubMed ID: 36167571
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Profiles of immune cell infiltration in head and neck squamous carcinoma.
    Liang B; Tao Y; Wang T
    Biosci Rep; 2020 Feb; 40(2):. PubMed ID: 32095823
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification of the HNSC88 Molecular Signature for Predicting Subtypes of Head and Neck Cancer.
    Chuang YH; Lin CY; Lee JC; Lee CH; Liu CL; Huang SH; Lee JY; Lai WS; Yang JM
    Int J Mol Sci; 2023 Aug; 24(17):. PubMed ID: 37685875
    [TBL] [Abstract][Full Text] [Related]  

  • 7. FOXD1 expression in head and neck squamous carcinoma: a study based on TCGA, GEO and meta-analysis.
    Huang J; Liang B; Wang T
    Biosci Rep; 2021 Jul; 41(7):. PubMed ID: 34269372
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The characteristics and clinical relevance of tumor fusion burden in head and neck squamous cell carcinoma.
    He L; Ren D; Lv G; Mao B; Wu L; Liu X; Gong L; Liu P
    Cancer Med; 2023 Jan; 12(1):852-861. PubMed ID: 35621268
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comprehensive characterization of the alternative splicing landscape in head and neck squamous cell carcinoma reveals novel events associated with tumorigenesis and the immune microenvironment.
    Li ZX; Zheng ZQ; Wei ZH; Zhang LL; Li F; Lin L; Liu RQ; Huang XD; Lv JW; Chen FP; He XJ; Guan JL; Kou J; Ma J; Zhou GQ; Sun Y
    Theranostics; 2019; 9(25):7648-7665. PubMed ID: 31695792
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Special AT-rich Sequence Binding-Protein 1 (SATB1) Correlates with Immune Infiltration in Breast, Head and Neck, and Prostate Cancer.
    Ge H; Yan Y; Yan M; Guo L; Mao K
    Med Sci Monit; 2020 Jun; 26():e923208. PubMed ID: 32562536
    [TBL] [Abstract][Full Text] [Related]  

  • 11. TPPP3 Associated with Prognosis and Immune Infiltrates in Head and Neck Squamous Carcinoma.
    Yang Z; Li X; Li J; Su Q; Qiu Y; Zhang Z; Zhang L; Mo W
    Biomed Res Int; 2020; 2020():3962146. PubMed ID: 33083464
    [TBL] [Abstract][Full Text] [Related]  

  • 12. LPAR2 correlated with different prognosis and immune cell infiltration in head and neck squamous cell carcinoma and kidney renal clear cell carcinoma.
    Sun K; Chen RX; Li JZ; Luo ZX
    Hereditas; 2022 Mar; 159(1):16. PubMed ID: 35241179
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Exostoisns (EXT1/2) in Head and Neck Cancers: An In Silico Analysis and Clinical Correlates.
    Wang Y; Huang Y; Zhu H; Guo Z; Cheng J; Zhang C; Zhong M
    Int Dent J; 2024 Jun; 74(3):446-453. PubMed ID: 37989698
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Biomarker Potential of
    Ju Y; Zhu F; Fang B
    Int J Med Sci; 2024; 21(5):921-936. PubMed ID: 38617010
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Integrated analysis of diagnostic, prognostic value and potential drug treatment of GSDME in head and neck squamous cell carcinoma.
    Hu R; Lu M; She L
    Eur Arch Otorhinolaryngol; 2023 Sep; 280(9):4239-4253. PubMed ID: 37204444
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Peroxisome proliferator-activated receptors signature reveal the head and neck squamous cell carcinoma energy metabolism phenotype and clinical outcome.
    Yao Y; Wang D; Zhang Y; Tang Q; Xu Z; Qin L; Qu Y; Yan Z
    J Gene Med; 2024 Jan; 26(1):e3605. PubMed ID: 37932968
    [TBL] [Abstract][Full Text] [Related]  

  • 17.
    Dai Y; Chen W; Huang J; Cui T
    Biomed Res Int; 2021; 2021():8874578. PubMed ID: 34285919
    [TBL] [Abstract][Full Text] [Related]  

  • 18. NT5E upregulation in head and neck squamous cell carcinoma: A novel biomarker on cancer-associated fibroblasts for predicting immunosuppressive tumor microenvironment.
    Chen XM; Liu YY; Tao BY; Xue XM; Zhang XX; Wang LL; Zhong H; Zhang J; Yang SM; Jiang QQ
    Front Immunol; 2022; 13():975847. PubMed ID: 36091055
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Effect of
    Yao YF; Liu W; Zhou ML; Qiu TL; Wang K
    Sichuan Da Xue Xue Bao Yi Xue Ban; 2022 May; 53(3):457-465. PubMed ID: 35642155
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Overexpression of XRCC1 is Associated with Poor Survival in Patients with Head and Neck Squamous Carcinoma and Has Potential to Be Used as Targeted Therapy by Synthetic Lethality.
    Ahirwar SS; Lasunte S; Gupta M; Chowdhary R; Kotnis A
    Asian Pac J Cancer Prev; 2023 Oct; 24(10):3525-3535. PubMed ID: 37898859
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.